ATM and neoplasm: For example, applying the BOADICEA V5 model for HRD/DDR gene germline carrier risk (ATM, CHEK2, BRCA1, BRCA2, BRIP1, PALB2, RAD51C and RAD51D) to the 22 breast cancer patients with germline pathogenic variants in these genes not detected by tumor-only sequencing, only 10 patients fell below the 10% pre-test probability cut-off, whereas 4 fell below the 5% cut-off.